January 16, 2017 10:43 AM ET


Company Overview of Dermira, Inc.

Company Overview

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company’s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which is in Phase III clinical trial for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and DRM01, a small-molecule sebum inhibitor, which is in Phase IIb clinical trial for the treatment of a...

275 Middlefield Road

Suite 150

Menlo Park, CA 94025

United States

Founded in 2010

62 Employees



Key Executives for Dermira, Inc.

Co-Founder, Chairman and Chief Executive Officer
Age: 64
Total Annual Compensation: $465.0K
Co-Founder, Chief Medical Officer, Director and Member of Science & Technology Committee
Age: 74
Total Annual Compensation: $350.0K
Chief Financial Officer and Chief Operating Officer
Age: 48
Total Annual Compensation: $355.0K
Compensation as of Fiscal Year 2015.

Dermira, Inc. Key Developments

Dermira, Inc Appoints of Lori Lyons-Williams as Chief Commercial Officer

Dermira, Inc. announced the appointment of Lori Lyons-Williams as Chief Commercial Officer. In this new role, Lori will be responsible for developing and implementing the commercial strategy for Dermira’s Phase 3 product candidates: CIMZIA® (certolizumab pegol), in development in collaboration with UCB Pharma S.A. Prior to joining Dermira, she spent 15 years in positions of increasing responsibility within the sales and marketing organization at Allergan, most recently as Vice President, Sales & Marketing for the Urology franchise.

Dermira Initiates Phase 3 Clinical Program in Acne

Dermira, Inc. announced dosing of the first patients in the Phase 3 program evaluating the safety and efficacy of olumacostat glasaretil (formerly DRM01), a novel, small molecule designed to reduce sebum production following topical application, in patients with acne vulgaris. The start of the olumacostat glasaretil Phase 3 clinical program is an important milestone for Dermira and puts one step closer to potentially offering patients a new, topical treatment option that targets an underlying cause of acne that is not addressed by available topical therapies. The Phase 3 clinical program consists of two randomized, multi-center, double-blind, parallel-group, vehicle-controlled trials, CLAREOS-1 and CLAREOS-2, designed to assess the safety and efficacy of olumacostat glasaretil compared to vehicle to support a potential New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA). The program is expected to enroll a total of approximately 1,400 patients ages nine and older with moderate-to-severe acne vulgaris at approximately 100 sites in the United States, Canada and Australia. In each trial, approximately 700 patients will be randomized and instructed to apply either olumacostat glasaretil at a concentration of 5.0% or vehicle, in a 2:1 fashion, twice daily to the face for 12 weeks.

Dermira, Inc. Appoints Emmanuel Caeymaex as Class II Director

Dermira, Inc. elected Emmanuel Caeymaex as a Class II director, effective January 1, 2017 to hold office for a term expiring at the 2019 annual meeting of stockholders.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Dermira, Inc., please visit www.dermira.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.